Study guide

18.2 Parenteral, TPN & Cytotoxic Preparation

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

18.2 Parenteral, TPN & Cytotoxic Preparation

Key Takeaways Explain This Topic AI

Calcium-phosphate precipitation is the classic TPN incompatibility; solubility depends on the Ca/Ph product, temperature, amino acid concentration, and the calcium salt used (calcium gluconate is more soluble than calcium chloride).

A 3-in-1 (total nutrient admixture) TPN combines dextrose, amino acids, and lipids in one bag; a 2-in-1 omits lipids and hangs them separately, which is preferred when lipid stability is a concern.

TPN hang time is generally limited to 24 hours because lipid-containing admixtures support microbial growth and physicochemical stability declines over time.

USP <800> requires hazardous drug compounding in a containment primary engineering control (Class II BSC or CACI), negative-pressure compounding area, double chemo-rated gloves, impervious gowns, and closed-system transfer devices (CSTDs).

A Class II B2 BSC exhausts 100% of its air to the outside with no recirculation, making it the preferred cabinet for cytotoxic compounding.

Last updated: August 2026

Parenteral preparations are administered by a route that bypasses gastrointestinal and skin barriers, so compatibility and sterility are equally critical. The DHA Pharmacist blueprint tests two distinct knowledge sets here: (1) the physicochemical compatibility of parenteral nutrition components, especially calcium-phosphate interactions, and (2) the containment requirements for hazardous and cytotoxic drugs under USP <800> .

Parenteral Nutrition Components

A total parenteral nutrition (TPN) formulation typically contains:

  • Amino acids — the nitrogen source
  • Dextrose — the carbohydrate/energy source
  • Lipids (intravenous fat emulsion) — calorie source and essential fatty acids
  • Electrolytes — sodium, potassium, magnesium, calcium, phosphate, chloride, acetate
  • Trace elements — zinc, copper, chromium, manganese, selenium
  • Vitamins — multivitamin preparation; some components (e.g., riboflavin, vitamin A) are light-sensitive

A 2-in-1 admixture contains dextrose and amino acids only; lipids are infused separately via a Y-site. A 3-in-1 (total nutrient admixture, TNA) combines dextrose, amino acids, and lipids in a single bag. The 3-in-1 is convenient and reduces line-handling, but lipids can destabilize the emulsion and shorten the permissible hang time.

Calcium-Phosphate Precipitation

The single most tested parenteral incompatibility is calcium-phosphate precipitation . When calcium and phosphate ions exceed their solubility product in the TPN, insoluble calcium phosphate crystals form and can embolize to pulmonary capillaries.

Key factors that affect calcium-phosphate solubility:

  • Factor Effect on solubility
  • Ca × Ph concentration product Higher product → more precipitation
  • Temperature Higher temperature during storage increases precipitation risk
  • Amino acid concentration Higher amino acid concentration increases solubility (complexes calcium)
  • pH Lower pH (more acidic) increases solubility
  • Calcium salt Calcium gluconate is more soluble than calcium chloride at equal elemental calcium
  • Order of mixing Add phosphate before calcium; never mix concentrated calcium and phosphate directly

Exam trap: Calcium gluconate, not calcium chloride, is the preferred salt for neonatal and adult TPN because it produces a lower localized calcium concentration at the injection site and a lower precipitation risk. The traditional rule of "phosphate first, calcium last" is a sequence safeguard, not a substitute for calculating the Ca/Ph product against published solubility curves.

Incompatibilities — General Principles

Beyond calcium-phosphate, parenteral incompatibilities fall into physicochemical categories:

Precipitation — visible or invisible solid formation (e.g., calcium phosphate, ceftriaxone-calcium).

pH-mediated incompatibility — many drugs are soluble only at a narrow pH range; mixing an acidic and an alkaline drug can precipitate one of them.

Ionic incompatibility — oppositely charged drugs or ions form insoluble complexes.

Adsorption — drug binds to infusion-set materials (e.g., nitroglycerin to PVC).

Light degradation — photolabile drugs (some vitamins, amphotericin B) require light protection.

Hang Time and Stability

TPN hang time is generally limited to 24 hours once the infusion begins, because lipid-containing admixtures can support microbial growth and because emulsion stability degrades over time. For 3-in-1 admixtures, some institutions shorten hang time further. Lipids infused alone (as in 2-in-1 setups) typically have a 12-hour hang limit because the emulsion is a growth medium.

Some vitamins (notably vitamin A and riboflavin) degrade on light exposure, so TPN bags may be protected from light during storage and infusion when stability data require it.

Cytotoxic and Hazardous Drug Preparation — USP <800>

USP <800> governs handling of hazardous drugs (HDs) — antineoplastics, some hormones, certain antivirals, and other agents identified by the National Institute for Occupational Safety and Health (NIOSH). The chapter applies to the entire HD lifecycle: receipt, storage, compounding, dispensing, administration, and disposal.

Engineering and PPE requirements for HD sterile compounding:

Requirement Specification

Containment PEC Class II BSC (Type B2 preferred) or compounding aseptic containment isolator (CACI); externally vented

Containment secondary engineering control (C-SEC) Negative-pressure room (typically −0.01 to −0.03 inches water gauge relative to adjacent areas); ≥12 air changes per hour

PPE — gloves Double chemo-rated gloves tested to ASTM D6978

PPE — gown Impervious, closed-front, long-sleeved, cuffed; changed every 2–3 hours or immediately if contaminated

PPE — face/eyes Eye and face protection when splashing is possible; respirator (NIOSH-approved) for spill response

  • Transfer Closed-system transfer devices (CSTDs) for compounding and administration
  • Waste Trace-contaminated waste segregated and disposed per hazardous-waste regulations
  • Spill Dedicated HD spill kit; spill procedures documented and rehearsed

Why a Class II B2? A Class II B2 BSC recirculates no air to the operator — 100% of the contaminated airflow is exhausted through HEPA filtration to the outside. This protects both the product (from the operator's microbial shed) and the operator (from hazardous drug aerosols and vapors). A Class II A2 recirculates a portion of air and is not preferred for high-risk cytotoxic work.

Closed-system transfer devices (CSTDs) mechanically prevent drug aerosol and vapor from escaping during reconstitution, transfer, and administration. USP <800> requires CSTDs for administration and recommends them for compounding; they are a key exam concept for HD handling.

Exam trap: Hazardous drug compounding must never occur in a horizontal LAFW. The horizontal airflow would direct hazardous aerosols toward the operator's face. Use a containment PEC (BSC or CACI) under negative pressure, separate from the non-hazardous compounding area.

Administration-Side Considerations

Cytotoxic administration also requires PPE: double chemo gloves, impervious gown, eye protection, and a CSTD on the IV line. Spills are managed with a designated HD spill kit (absorbent pads, spill control pillows, chemo-rated gloves, gown, face shield, scoop, and hazardous-waste bag). Contaminated PPE and disposable materials are disposed of as trace chemotherapy waste, typically in yellow or blue chemo-rated containers.